Advertisement
Research Article| Volume 10, ISSUE 1, P39-57, March 1990

Tumor Markers in Endocrine Malignancies

  • Ronald A. DeLellis
    Correspondence
    Address reprint requests to: Ronald A. DeLellis, MD, Department of Pathology, New England Medical Center Hospital, 750 Washington Street, Boston, MA 02111
    Affiliations
    Professor of Pathology, Tufts University School of Medicine; Senior Pathologist, New England Medical Center Hospital, Boston, Massachusetts.
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30581-X
Tumor Markers in Endocrine Malignancies
Previous ArticleCancer Markers of the 1990s: Comparison of the New Generation of Markers Defined by Monoclonal Antibodies and Oncogene Probes to Prototypic Markers
Next ArticleImmunohfstochemistry in Surgical Pathology: The Case of the Undifferentiated Malignant Neoplasm
      This paper is only available as a PDF. To read, Please Download here.
      The development of assay techniques for the analysis of tumor markers in tissue extracts and in the peripheral circulation has had a major impact on the diagnosis and management of patients with endocrine neoplasms. In addition to eutopic and ectopic hormones, a variety of other tumor-derived products, including endocrine secretory proteins, enzymes, and oncodevelopmental antigens, can be assayed. The development of stimulatory tests to evaluate secretory reserve has been of particular value for the early detection of endocrine tumors and preneoplastic lesions in the multiple endocrine neoplasia syndromes. In addition, analysis of tumor markers has been of considerable importance for estimating total tumor burden and assessing responses to various therapeutic modalities. Recent advances in molecular biologic and cytogenetic technologies have the potential for prenatal detection of some forms of the inherited multiple endocrine neoplasia syndromes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Baylin S.
        • Mendelsohn G.
        Ectopic (inappropriate) hormone production by tumors: Mechanisms involved and the biological and clinical implications.
        Endocr Rev. 1980; 1:45
        • Baylin S.
        • Mendelsohn G.
        Time-dependent changes in human tumors: Implications for diagnosis and clinical behavior.
        Semin Oncol. 1982; 9: 504
        • Bishop A.E.
        • Sekiya K.
        • Salahuddin M.J.
        • et al.
        The distribution of GAWK-like immunoreactivity in neuroendocrine cells of the human gut, pancreas, adrenal and pituitary glands and its colocalization with chromogranin B.
        Histochemistry. 1989; 90: 475
        • Black E.G.
        • Sheppard M.C.
        • Hoffenberg R.
        Serial thyroglobulin measurements in the management of differentiated thyroid carcinoma.
        Clin Endocrinol. 1987; 27: 115
        • Borer W.Z.
        Ectopic hormones as tumor markers.
        Clin Lab Med. 1984; 4: 775
        • Brandi M.L.
        • Aurbach G.D.
        • Fitzpatrick L.A.
        • et al.
        Parathyroid mitogenic activity in plasma from patients with familial multiple endocrine neoplasia type 1.
        N Engl J Med. 1986; 314: 1287
        • Cutz E.
        • Chan W.
        • Track N.S.
        Bombesin, calcitonin and leu-enkephalin immunoreactivity in endocrine cells of the human lung.
        Experientia. 1981; 37: 765
        • DeBold C.R.
        • Menefeet J.K.
        • Nicholson W.E.
        • et al.
        Proopiomelanocortin gene is expressed in many normal human tissues and in tumors not associated with ectopic adrenocorticotropin syndrome.
        Mol Endocrinol. 1988; 2: 862
        • DeLellis R.A.
        Immunohistochemistry of neoplasia. Endocrine tumors.
        in: Colvin R.B. Bhan A.K. McCluskey R.T. Diagnostic Immunopathology. Raven Press, New York1988: 301-338
        • DeLellis R.A.
        • Dayal Y.
        • Tischler A.S.
        • et al.
        Multiple endocrine neoplasia (MEN) syndromes: Cellular origins and interrelationships.
        Int Rev Exp Pathol. 1986; 28: 163
        • DeLellis R.A.
        • Rule A.H.
        • Spiler I.
        • et al.
        Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma.
        Am J Clin Pathol. 1978; 70: 587
        • DeLellis R.A.
        • Wolfe H.J.
        The pathobiology of the human calcitonin (C)-cell: A review.
        Pathol Annu 16(Part 2). 1981; 25
        • Dickson C.
        • Peters G.
        Potential oncogene product related to growth factors.
        Nature. 1987; 326: 833
        • Eiden L.E.
        • Huttner W.B.
        • Mallet J.
        • et al.
        A nomenclature proposal for the chromogranin/secretogranin proteins.
        Neuroscience. 1987; 21: 1019
        • Farid N.R.
        • Buchler S.
        • Russell N.A.
        • et al.
        Prolactinomas in familial multiple endocrine neoplasia syndrome-type I.
        Am J Med. 1980; 69: 874
        • Feldman J.M.
        Monoamine and diamine oxidase activity in the diagnosis of carcinoid tumors.
        Cancer. 1985; 56: 2855
        • Fischbach W.
        • Schwarz-Wallrauch C.
        • Jany B.
        Neuron specific enolase and thymidine kinase as an aid to the diagnosis, treatment and monitoring of small cell lung cancer.
        Cancer. 1989; 63: 1143
        • Franc B.
        • Chayvialle J.A.
        • Modigliani E.
        • et al.
        Plasma and tumor levels of somatostatin and somatostatin immunohistochemistry in medullary thyroid carcinoma: Apparently discrepant preliminary results.
        Henry Ford Hosp Med J. 1987; 35: 147
        • Friedman E.
        • Sakaguchi K.
        • Bale A.E.
        • et al.
        Clonality of parathyroid tumors in familial multiple endocrine neoplasia type I.
        N Engl J Med. 1989; 321: 213
        • Friesen S.R.
        Surgical Endocrinology, Clinical Syndromes. J.B. Lippin-cott, Philadelphia1978
        • Gagel R.F.
        • Tashjian Jr., A.H.
        • Cummings T.
        • et al.
        Impact of prospective screening for multiple endocrine neoplasia type 2.
        Henry Ford Med J. 1987; 35: 94
        • Gagel R.F.
        • Tashjian Jr., A.H.
        • Cummings T.
        • et al.
        The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience.
        N Engl J Med. 1988; 318: 478
        • Girgis S.I.
        • Lynch C.
        • Hillyard C.J.
        Calcitonin gene peptides: The diagnostic value of measurement in medullary thyroid carcinoma.
        Henry Ford Hosp Med J. 1987; 35: 118
        • Gould V.E.
        The endocrine lung.
        Lab Invest. 1983; 48: 507
        • Heitz P.U.
        • Kasper M.
        • Kloppel G.
        • et al.
        Glycoprotein-hormone alpha chain production by pancreatic endocrine tumors: A specific marker for malignancy.
        Cancer. 1983; 51: 227
        • Howanitz J.H.
        • Howanitz P.J.
        Pituitary tumors.
        Clin Lab Med. 1984; 4: 643
        • Ishikawa N.
        • Hamada S.
        Association of medullary carcinoma of the thyroid with carcinoembryonic antigen.
        Br J Cancer. 1976; 34: 111
        • Jackson C.E.
        • Norum R.A.
        • Talpos G.B.
        • et al.
        Clinical value of calcitonin and carcinoem-bryonic antigen doubling times in medullary thyroid carcinoma.
        Henry Ford Hosp Med J. 1987; 35: 120
        • Jameson L.J.
        • Klibanski A.
        • Black P.M.
        • et al.
        Glycoprotein hormone genes are expressed in clinically non-functioning pituitary adenomas.
        J Clin Invest. 1987; 80: 1472
        • Jorgensen L.G.M.
        • Hansen H.H.
        • Cooper E.H.
        Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer.
        Eur J Cancer Clin Oncol. 1989; 25: 123
        • Kahn C.R.
        • Rosen S.W.
        • Weintraub B.D.
        • et al.
        Ectopic production of chorionic gonadotropin and its subunits by islet cell tumors. A specific marker for malignancy.
        N Engl J Med. 1977; 297: 565
        • Kleinberg D.L.
        • Noel G.L.
        • Frantz A.G.
        Galactorrhea: A study of 235 cases, including 48 with pituitary tumors.
        N Engl J Med. 1977; 296: 589
        • Kloppel G.
        • Heitz P.U.
        Pancreatic Pathology. Churchill Livingstone, Edinburgh1984
        • Lippman S.M.
        • Mendelsohn G.
        • Trump D.L.
        • et al.
        The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma. A study of calcitonin, L-dopa decarboxylase and histaminase.
        J Clin Endocrinol Metab. 1982; 54: 233
        • Lips C.M.J.
        • Vasen H.F.A.
        • Lamers C.B.H.W.
        Multiple endocrine neoplasia syndrome.
        CRC Crit Rev Oncol Hematol. 1987; 2: 117
        • Lloyd R.V.
        • Iacangelo A.
        • Eiden L.E.
        Chromogranin A and B messenger ribonucleic acids in pituitary and other normal and neoplastic human endocrine tissues.
        Lab Invest. 1989; 60: 548
        • Matthew C.G.P.
        • Chin K.S.
        • Easton D.F.
        • et al.
        A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10.
        Nature. 1987; 328: 527
        • McGuigan J.E.
        • Wolfe M.M.
        Secretin injection test in the diagnosis of gastrinoma.
        Gas troenterology. 1980; 79: 1324
        • Mendelsohn G.
        Diagnosis and Pathology of Endocrine Disease. J.B. Lippincott, Philadelphia1988
        • Oberg K.
        • Grimelius L.
        • Lundqvist G.
        • et al.
        Update on pancreatic polypeptide as a serum marker for endocrine tumors of the pancreas and gut.
        Acta Med Scand. 1981; 210: 145
        • O’Connor D.T.
        • Deftos L.J.
        Secretion of chromogranin A by peptide producing endo crine neoplasms.
        N Engl J Med. 1986; 314: 1145
        • Prinz R.A.
        • Marangos P.J.
        Serum markers for pancreatic islet cell and intestinal carcinoidtumors: A comparison of neuron specific enolase, beta human chorionic gonadotropin and pancreatic polypeptide.
        Surgery. 1983; 94: 1019
        • Rood R.P.
        • DeLellis R.A.
        • Dayal Y.
        • et al.
        Pancreatic cholera syndrome due to a vasoactive intestinal polypeptide producing tumor: Further insights into the pathophysiology.
        Gastroenterology. 1988; 94: 813
        • Rougier P.H.
        • Calmettes C.
        • Laplanche A.
        The values of calcitonin and carcinoembryonic antigen in the treatment and management of non-familial medullary thyroid carcinoma.
        Cancer. 1983; 51: 855
        • Rule A.H.
        • DeLellis R.A.
        • Tashjian Jr., A.H.
        • et al.
        Calcitonin and carcinoembryonic antigen: Tumor markers in medullary thyroid carcinoma.
        in: Lehmann F.G. Carcino-Em-bryonic Proteins. II. Biomedical Press, New York, Elsevier/North Holland1979: 781
        • Schmidt W.E.
        • Siegel E.G.
        • Lamberts E.
        • et al.
        Pancreastatin: Molecular and immunocyto-chemical characterization of a novel peptide in porcine and human tissues.
        Endocrinology. 1988; 123: 1395
        • Sheppard M.C.
        Serum thyroglobulin and thyroid cancer.
        Q J Med. 1986; 59: 429
        • Simpson N.E.
        • Kidd K.K.
        • Goodfellow P.J.
        • et al.
        Assignment of multiple endocrine neopla sia type 2a to chromosome 10 by linkage.
        Nature. 1987; 328: 528
        • Sipple J.H.
        Multiple endocrine neoplasia type 2 syndromes: Historical perspectives.
        Henry Ford Hosp Med J. 1984; 32: 219
        • Sobol R.E.
        • Memoli V.
        • Deftos L.J.
        Hormone-negative chromogranin A-positive endo crine tumors.
        N Engl J Med. 1989; 320: 444
        • Sobol R.E.
        • O’Connor D.T.
        • Addison D.T.
        • et al.
        Elevated serum chromogranin A concen trations in small cell lung carcinoma.
        Ann Int Med. 1986; 105: 698
        • Telenius-Berg M.
        • Berg B.
        • Hamberger B.
        • et al.
        Screening for early asymptomatic pheochromocytoma in MEN-2.
        Henry Ford Med J. 1987; 35: 110
        • Thakker R.V.
        • Bouloux P.
        • Woodnig C.
        • et al.
        Association of parathyroid tumors in multi ple endocrine neoplasia type I with loss of alleles on chromosome 11.
        N Engl J Med. 1989; 321: 218
        • Villiard J.L.
        • Tiget F.
        • Hartmann O.
        • et al.
        Serum neuron specific/non-neuronal enolase ratio in the diagnosis of neuroblastomas.
        Cancer. 1988; 62: 2546
        • Wells S.A.
        • Haagensen D.E.
        • Lineham W.M.
        • et al.
        The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma.
        Cancer. 1978; 42: 1498
        • Wermer P.
        Genetic aspects of adenomatosis of endocrine glands.
        Am J Med. 1954; 16: 362
        • Wilson J.B.
        • Foster D.W.
        Williams’ Textbook of Endocrinology. ed 7. W.B. Saunders, Philadelphia1985
        • Wilson B.S.
        • Lloyd R.V.
        Detection of chromogranin in neuroendocrine cells with a monoclonal antibody.
        Am J Pathol. 1984; 115: 458

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30581-X

      Copyright

      © 1990 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX